NanoViricides logo
NanoViricides
NNVC | AMEX
Chart Builder DCF Calculator
$1.24
+$0.01 (+0.81%)
At close: Nov 16, 2026, 4:00 PM ET
$1.23
-$0.01 (-0.81%)
After-hours: Nov 16, 2026, 5:09 PM ET

NanoViricides Company Profile

Company profile explained

Company Profile

NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.

Key Executives

Name Position
Anil R. Diwan Executive Chairman, President, Chief Executive Officer & Secretary
Meeta R. Vyas Chief Financial Officer & Compliance Officer

Latest SEC Filings

Date Type Title
Oct 21, 2026 424B5 Filing
Oct 08, 2026 DEF 14A Filing
Sep 29, 2026 8-K Current Report
Sep 28, 2026 10-K Annual Report
Sep 03, 2026 424B3 Filing
Aug 31, 2026 EFFECT Filing
Aug 21, 2026 S-3 Filing
Jul 30, 2026 8-K Current Report
Jul 27, 2026 424B5 Filing
Jul 27, 2026 424B5 Filing
View All SEC Filings ➞
NanoViricides
NanoViricides logo
Country United States
IPO Date Oct 26, 2005
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Anil R. Diwan

Contact Details

1 Controls Drive Shelton, Connecticut 06484 United States

Stock Details

Ticker Symbol NNVC
Exchange AMEX
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001379006
CUSIP Number 630087302
ISIN Number US6300873022
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.